Reproductive Medicine Center, Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Front Endocrinol (Lausanne). 2020 Dec 4;11:539427. doi: 10.3389/fendo.2020.539427. eCollection 2020.
Previous studies suggested that singletons from frozen-thawed embryo transfer (FET) were associated with higher risk of large, post-date babies and adverse obstetrical outcomes compared to fresh transfer and natural pregnancy. No data available revealed whether the adverse perinatal outcomes were associated with aberrantly high progesterone level from different endometrium preparations in HRT-FET cycle. This study aimed to compare the impact of progesterone intramuscularly and vaginally regimens on neonatal outcomes in HRT-FET cycles.
A total of 856 HRT-FET cycles from a fertility center from 2015 to 2018 were retrospectively analyzed. All patients had their first FET with two cleavage-staged embryos transferred. Endometrial preparation was performed with sequential administration of estrogen followed by progesterone intramuscularly 60 mg per day or vaginal gel Crinone 90 mg per day. Pregnancy outcomes including live birth rate, singleton birthweight, large for gestational age (LGA) rate, small for gestational age (SGA) rate, and preterm delivery rate were analyzed. Student's t test, Mann-Whitney U-test, Chi square analysis, and multivariable logistic regression were used where appropriate. Differences were considered significant if p < 0.05.
No significant difference of live birth rate was found between different progesterone regimens (Adjusted OR 1.128, 95% CI 0.842, 1.511, p = 0.420). Neonatal outcomes like singleton birthweight (p = 0.744), preterm delivery rate (Adjusted OR 1.920, 95% CI 0.603, 6.11, p = 0.269), SGA (Adjusted OR 0.227, 95% CI 0.027, 1.934, p = 0.175), and LGA rate (Adjusted OR 0.862, 95% CI 0.425, 1.749, p=0.681) were not different between two progesterone regimens. Serum P level >41.82 pmol/L at 14 day post-FET was associated with higher live birth rate than serum P level ≤41.82 pmol/L in HRT-FET cycles when progesterone was intramuscularly delivered (Adjusted OR 1.690, 95% CI 1.002, 2.849, p = 0.049). But singleton birthweight, preterm delivery rate, SGA and LGA rate were not different between these two groups.
Relatively higher serum progesterone level induced by intramuscular regimen did not change live birth rate or neonatal outcomes compared to vaginal regimen. Monitoring serum progesterone level and optimizing progesterone dose of intramuscular progesterone as needed in HRT-FET cycles has a role in improving live birth rate without impact on neonatal outcomes.
先前的研究表明,与新鲜胚胎移植和自然妊娠相比,冷冻解冻胚胎移植(FET)的单胎妊娠与大胎龄儿、不良产科结局的风险更高。目前尚无数据显示,不同的孕激素子宫内膜准备方案在 HRT-FET 周期中是否与孕激素水平异常升高有关。本研究旨在比较孕激素肌内和阴道方案对 HRT-FET 周期新生儿结局的影响。
回顾性分析了 2015 年至 2018 年期间一家生育中心的 856 例 HRT-FET 周期。所有患者均接受了第一次 FET,移植了两个卵裂期胚胎。子宫内膜准备采用雌激素序贯治疗,随后每天肌内注射 60mg 孕激素或阴道凝胶 Crinone 90mg。分析了包括活产率、单胎出生体重、巨大儿(LGA)率、小于胎龄儿(SGA)率和早产率在内的妊娠结局。使用学生 t 检验、Mann-Whitney U 检验、卡方分析和多变量逻辑回归(如果适用)。如果 p<0.05,则认为差异具有统计学意义。
不同孕激素方案的活产率无显著差异(调整后的 OR 1.128,95%CI 0.842,1.511,p=0.420)。新生儿结局如单胎出生体重(p=0.744)、早产率(调整后的 OR 1.920,95%CI 0.603,6.11,p=0.269)、SGA(调整后的 OR 0.227,95%CI 0.027,1.934,p=0.175)和 LGA 率(调整后的 OR 0.862,95%CI 0.425,1.749,p=0.681)在两种孕激素方案之间无差异。当孕激素肌内给药时,FET 后 14 天血清 P 水平>41.82pmol/L 与血清 P 水平≤41.82pmol/L 相比,活产率更高(调整后的 OR 1.690,95%CI 1.002,2.849,p=0.049)。但两组间单胎出生体重、早产率、SGA 和 LGA 率无差异。
与阴道方案相比,肌内方案引起的血清孕激素水平升高并不会改变活产率或新生儿结局。在 HRT-FET 周期中监测血清孕激素水平并根据需要优化孕激素肌内孕激素剂量,有助于提高活产率,而不会影响新生儿结局。